Short answer: we do not know yet. A Swedish team has published a phase IIa, open-label, randomized controlled trial protocol to test whether two 25 mg psilocybin sessions with structured psychological support are safe and feasible for adolescents and young adults with recurrent anorexia nervosa compared with usual care. This is a protocol only, so there are no results. I cannot independently verify details beyond what the authors report.
The primary focus is safety and tolerability, monitored through adverse events and psychiatric and medical checks. Secondary outcomes track eating-disorder symptoms, relapse, mood, well-being, and personality for up to 12 months. The study is unblinded and includes exploratory measures such as 7T fMRI and blood BDNF to probe potential mechanisms.
Participants are ages 16 to 35 with prior partial weight restoration followed by relapse. Minors enter only after an interim safety review of adult data. The authors state recruitment began in 2026 and that first results are expected from 2029; I cannot verify this timeline independently.
Bottom line: safety and feasibility in youth remain unproven and should be assessed within regulated clinical trials. For a clear overview of the planned study, see this summary: psilocybin as a possible treatment for anorexia nervosa in youth.
We will have to wait for data before drawing conclusions.